Full text is available at the source.
Abstract
Mitochondria-targeted nanotherapeutics may represent a potential disease-modifying strategy for aging-related neurodegenerative disorders.
- Aging is associated with an increased risk of neurodegenerative disorders, including Huntington's, Alzheimer's, and Parkinson's diseases.
- Current diagnostic methods for these disorders have limited sensitivity and specificity, leading to challenges in early detection and treatment.
- Mitochondrial dysfunction is identified as a preliminary pathological feature of neurodegenerative disorders, potentially causing oxidative stress and bioenergetic failure.
- Nanotherapeutic approaches aim to deliver drugs directly to defective mitochondria, which could enhance mitochondrial function and protect neurons.
- Advancements in targeting efficacy, production scalability, and long-term safety are necessary for successful clinical application.
Simplified